Sapient’s discovery metabolomics services enable small molecule biomarker discovery at unprecedented speed and scale.

What We Enable

Discover more, develop faster, heal quicker.

Learn More

We created Sapient to drive a fundamental shift in today’s costly, slow moving, inefficient drug development process. As a discovery metabolomics lab, we help sponsors and researchers gain a deeper understanding of human biology and use biomarker-guided drug development to effectively align patients, disease, and specific therapies.

Our Platform

Integrated Biomarker Discovery Pipeline

Sapient’s integrated discovery platform leverages next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases to enable rapid discovery, population-level validation, and robust translation of small molecule biomarkers.

Drug Creation

High-throughput mass spectrometry technologies perform untargeted profiling of >15,000 small molecule biomarkers per biosample, in <1 minute per sample run.
Analytical Technologies
Data science algorithms and machine learning tools are applied to the data to reveal key biomarkers of biological processes, disease progression, and drug response.
Computational Analysis
Comprised of data from 100,000+ human biosamples, with more than 10-30 years of follow-up data across patients, this repository can be used to cross-validate identified biomarkers.
Human Biology Database

Together these technologies drive significant speed and scale advantages.

Read Case Studies

Ability to assay


small molecule biomarkers per biosample

Capacity to analyze


biosamples per day

Pipeline to Translation

End-to-end support from discovery to clinical implementation.

Sapient is a high complexity CLIA-certified, CAP-accredited laboratory, which means we can support rapid translation of the biomarker discoveries we make to regulated clinical applications.

After we identify biomarkers of interest through initial rLC-MS discovery screening, we can use more traditional targeted methods to develop specific metabolites into clinical assays for use in CLIA settings, and can perform and deliver the test results under CLIA.